TME Pharma N.V. Market Cap ($7.34 Million)
Market Cap & Net Worth: TME Pharma N.V. (ALTME)
TME Pharma N.V. market cap. TME Pharma N.V. (PA:ALTME) has a market capitalization of $7.34 Million (€6.28 Million) as of November 8, 2026. Listed on the PA stock exchange, this France-based company holds position #27652 globally and #483 in its home market, demonstrating a -23.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TME Pharma N.V.'s stock price €0.11 by its total outstanding shares 94091417 (94.09 Million). Also see ALTME operating cash flow for how efficiently the company converts equity into cash flow.
TME Pharma N.V. Market Cap History (2016–2026)
TME Pharma N.V. market cap history from 2016 to 2026. Data shows change from $219.27 Billion to $11.79 Million (-62.11% CAGR). Check ALTME stock price and chart for real-time trading data and today's change.
TME Pharma N.V. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TME Pharma N.V.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is TME Pharma N.V. growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
434.22x
TME Pharma N.V.'s market cap is 434.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $219.27 Billion | $83.00K | -$10.75 Million | 2641804.02x | N/A |
| 2017 | $63.32 Billion | $234.00K | -$5.38 Million | 270589.76x | N/A |
| 2019 | $5.80 Billion | $154.00 | -$861.00K | 37683872.16x | N/A |
| 2020 | $5.60 Billion | $35.00 | -$10.40 Million | 160111209.10x | N/A |
| 2021 | $2.33 Billion | $33.00K | -$14.45 Million | 70705.77x | N/A |
| 2023 | $25.30 Million | $17.00K | -$6.74 Million | 1488.27x | N/A |
| 2024 | $8.25 Million | $19.00K | -$5.72 Million | 434.22x | N/A |
Competitor Companies of ALTME by Market Capitalization
Companies near TME Pharma N.V. in the global market cap rankings as of November 8, 2026. Also see TME Pharma N.V. asset portfolio for a full breakdown of the balance sheet.
Key companies related to TME Pharma N.V. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of TME Pharma N.V. (2016–2026)
Market capitalization of TME Pharma N.V. from 2016 to today. Between 2016 and today, TME Pharma N.V.'s market cap moved from $219.27 Billion to $ 11.79 Million, with a yearly change of -62.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.79 Million | +64.42% |
| 2025 | €7.17 Million | -13.07% |
| 2024 | €8.25 Million | -67.39% |
| 2023 | €25.30 Million | -79.13% |
| 2022 | €121.23 Million | -94.80% |
| 2021 | €2.33 Billion | -58.36% |
| 2020 | €5.60 Billion | -3.44% |
| 2019 | €5.80 Billion | -42.94% |
| 2018 | €10.17 Billion | -83.94% |
| 2017 | €63.32 Billion | -71.12% |
| 2016 | €219.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of TME Pharma N.V. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.34 Million USD |
| MoneyControl | $7.34 Million USD |
| MarketWatch | $7.34 Million USD |
| marketcap.company | $7.34 Million USD |
| Reuters | $7.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more